aTyr Pharma (ATYR) Competitors $1.00 -0.02 (-1.96%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$0.99 -0.01 (-1.10%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR vs. SCPH, TKNO, SOPH, NMRA, ALLO, JBIO, TECX, ABEO, GALT, and FENCShould you be buying aTyr Pharma stock or one of its competitors? The main competitors of aTyr Pharma include scPharmaceuticals (SCPH), Alpha Teknova (TKNO), SOPHiA GENETICS (SOPH), Neumora Therapeutics (NMRA), Allogene Therapeutics (ALLO), Jade Biosciences (JBIO), Tectonic Therapeutic (TECX), Abeona Therapeutics (ABEO), Galectin Therapeutics (GALT), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry. aTyr Pharma vs. Its Competitors scPharmaceuticals Alpha Teknova SOPHiA GENETICS Neumora Therapeutics Allogene Therapeutics Jade Biosciences Tectonic Therapeutic Abeona Therapeutics Galectin Therapeutics Adherex Technologies aTyr Pharma (NASDAQ:ATYR) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment. Which has more volatility & risk, ATYR or SCPH? aTyr Pharma has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Is ATYR or SCPH more profitable? aTyr Pharma has a net margin of 0.00% compared to scPharmaceuticals' net margin of -183.55%. aTyr Pharma's return on equity of -93.69% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets aTyr PharmaN/A -93.69% -68.83% scPharmaceuticals -183.55%-1,647.86%-71.76% Do analysts prefer ATYR or SCPH? aTyr Pharma presently has a consensus target price of $23.25, suggesting a potential upside of 2,225.00%. scPharmaceuticals has a consensus target price of $7.78, suggesting a potential upside of 37.27%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than scPharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00scPharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Does the media prefer ATYR or SCPH? In the previous week, aTyr Pharma had 38 more articles in the media than scPharmaceuticals. MarketBeat recorded 39 mentions for aTyr Pharma and 1 mentions for scPharmaceuticals. scPharmaceuticals' average media sentiment score of 0.88 beat aTyr Pharma's score of 0.19 indicating that scPharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 3 Very Positive mention(s) 3 Positive mention(s) 28 Neutral mention(s) 1 Negative mention(s) 4 Very Negative mention(s) Neutral scPharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, ATYR or SCPH? aTyr Pharma has higher earnings, but lower revenue than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioaTyr PharmaN/AN/A-$64.02M-$0.80-1.25scPharmaceuticals$49.97M6.05-$85.15M-$1.81-3.13 Do institutionals and insiders hold more shares of ATYR or SCPH? 61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are owned by institutional investors. 3.7% of aTyr Pharma shares are owned by company insiders. Comparatively, 4.8% of scPharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryaTyr Pharma beats scPharmaceuticals on 11 of the 15 factors compared between the two stocks. Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATYR vs. The Competition Export to ExcelMetricaTyr PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.95M$3.41B$6.08B$10.55BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-1.2522.9384.5927.19Price / SalesN/A486.15610.53132.96Price / CashN/A46.9737.8662.13Price / Book1.2010.5012.466.65Net Income-$64.02M-$52.47M$3.32B$276.79M7 Day Performance-5.66%2.90%2.29%1.75%1 Month Performance-2.44%15.36%9.66%5.15%1 Year Performance-62.26%14.29%75.05%36.96% aTyr Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATYRaTyr Pharma3.1963 of 5 stars$1.00-2.0%$23.25+2,225.0%-63.2%$99.95MN/A-1.2553Trending NewsGap DownSCPHscPharmaceuticals4.1547 of 5 stars$5.67flat$7.78+37.3%N/A$302.20M$49.97M-3.1330High Trading VolumeTKNOAlpha Teknova2.5714 of 5 stars$5.65+0.2%$10.00+77.0%-12.9%$301.83M$37.74M-13.45240Positive NewsSOPHSOPHiA GENETICS1.8472 of 5 stars$4.05-8.0%$8.00+97.5%+21.3%$297.35M$65.17M-9.20520News CoverageGap UpHigh Trading VolumeNMRANeumora Therapeutics2.011 of 5 stars$1.89+3.3%$7.14+277.9%-89.3%$296.36MN/A-1.20108ALLOAllogene Therapeutics3.1495 of 5 stars$1.38+3.8%$8.44+511.9%-55.4%$295.10M$20K-1.24310JBIOJade Biosciences2.0376 of 5 stars$9.14+3.2%$16.00+75.1%N/A$289.07MN/A-0.3020TECXTectonic Therapeutic2.591 of 5 stars$15.20-0.3%$80.29+428.2%-50.1%$285.17MN/A-3.76120News CoverageABEOAbeona Therapeutics4.238 of 5 stars$5.34-1.3%$19.50+265.2%-16.1%$277.42M$3.50M7.6390GALTGalectin Therapeutics1.201 of 5 stars$4.44+2.5%$6.00+35.1%+92.0%$277.38MN/A-6.949News CoverageFENCAdherex Technologies2.1009 of 5 stars$9.74-1.4%$13.33+36.9%+85.8%$275.76M$33.30M-23.1910Trending NewsAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies scPharmaceuticals Alternatives Alpha Teknova Alternatives SOPHiA GENETICS Alternatives Neumora Therapeutics Alternatives Allogene Therapeutics Alternatives Jade Biosciences Alternatives Tectonic Therapeutic Alternatives Abeona Therapeutics Alternatives Galectin Therapeutics Alternatives Adherex Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATYR) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
